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ABSTRACT
The Role of Viral Interleukin-6 in Tumor Development of
Kaposi’s Sarcoma-Associated Herpesvirus
Lymphomas
Rebecca A. Fullwood
Department of Microbiology and Molecular Biology, BYU
Master of Science
Kaposi’s sarcoma herpesvirus (KSHV) is a cancer-causing virus, primarily affecting
AIDS patients. KSHV is found in 3-10% of the U.S. population and can cause a range of cancers
in the highly immunosuppressed; these cancers include Kaposi’s sarcoma, pleural effusion
lymphoma (PEL) and multicentric Castleman’s disease (MCD). The current techniques for
treating these cancers are relatively ineffective, largely due to their inefficiency at targeting
tumors formed by the infection. One protein produced by KSHV, the viral homolog of
interleukin-6 (vIL-6), is thought to play a major role in tumor development post-infection. Here a
novel animal model is implemented to study the ways vIL-6 affects tumor development through
growth factors and other cytokines within infected highly immune-deficient Rag2-/-γc-/- mice.
Mice were subcutaneously injected with one of three types of cells: B cells infected with a wildtype (WT) KSHV, B cells infected with mutant KSHV without the gene for viral interleukin 6,
and a negative control of uninfected B cells. After allowing time for tumors to develop the mice
were sacrificed and the tumors assessed. Analysis of the physical properties of the tumors, as
well as markers expressed by the tumors, were used to help determine whether vIL-6 could be an
appropriate target when treating these cancers. In this study vIL-6 was seen to influence certain
B cell markers (CD30), as well as onset of tumors (with no significant increase in overall tumor
mass, but with marginally statistically significant increase in tumor number). This indicates that
although vIL-6 could play a small role as a target for cancer, further investigation into the
relationship of CD30 in these types of cancers needs to be explored. It was also found that the
KSHV viral-infection decreases the development of tumors compared with uninfected
immortalized B cells (BJAB). Not only would results from this experiment help develop new
treatments, and change the lives of those suffering with cancers induced by KSHV, but they
would provide a foundation for future studies with these types of cancers.

Key Words: Kaposi’s sarcoma-associated herpesvirus, KSHV, viral interleukin-6, cancer,
lymphoma
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Introduction
Cancer has justifiably been labeled “the emperor of all maladies.”1 As the second leading cause for death
in the United States2 and with over 100 different variations affecting humans3, these abnormal growths of
cells account for an unfathomable toll in individual suffering, along with expenses of $1.2 trillion per
year4. The scale and complexity of the disease presents a puzzle of gigantic proportions with millions of
scientists each working to solve a small piece. Cancer research can focus on one or more areas of the
sequence of events that accompanies the disease; these include agents that trigger genetic mutations in
cells (such as viruses), the nature of the genetic modifications, and the resultant consequences to cell
biology. This thesis attempts to make a small contribution to a specific area of the research effort that
involves the role of agents, such as viruses, in the development of cancer. A deeper look at the specialized
area of viral oncogenesis in humans is needed, with this research focusing on that of Kaposi’s sarcomaassociated herpesvirus (KSHV).
Background
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is a
virus that causes cancer in highly immunocompromised individuals5. First diagnosed in 1872 as a slowgrowing neoplasm in elderly men of the Mediterranean by Moritz Kaposi6, Kaposi’s sarcoma (KS) became
a global concern when a more aggressive and rapidly fatal strain of the virus was identified amongst the
homosexual populations in 19817,8. The virus went on to infect 15% of all registered acquired immune
deficiency syndrome (AIDS) patients in the United States by 19899, bringing about a dire need for stronger
research into what was causing these illnesses and how best to treat them.
Although infections associated with the virus were becoming increasingly concerning amongst the
scientific community, the agent causing this epidemic was not identified until 199410. This has made it
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one of the most recent oncogenic viruses to be studied. Loss of immune function caused by human
immunodeficiency virus (HIV) leaves AIDS patients more susceptible to the oncogenic properties of this
virus, which would not manifest in a healthy person11. The potential for this virus to become oncogenic in
compromised individuals can lead to serious cancers, and many times death for those already suffering
with various infections due to AIDS.
In the following sections we briefly review the nature of herpesviruses in general, and more specifically
the KSHV strain, and its role in cancer formation and propagation. Finally, we review the potential role
of a specific protein, vIL-6, in facilitating cancer formation and growth. The main body of the thesis will
investigate prospective correlations between KSHV-induced cancers and the presence of vIL-6 in
susceptible cells. It is hoped that the search for such interactions during the cancer evolution will lead to
new insights for potential control or eradication of this sub-family of cancer diseases.
Herpesviruses
Kaposi’s sarcoma associated herpesvirus (KSHV) is one member of the larger herpesviridae family.
Among the 130+ members of this family12, nine are known to be human herpesviruses (HHV) that affect
the populous. The genomes of these viruses are somewhat large (124-230kb), double-stranded DNA
genomes, enclosed by an icosahedral capsid and an envelope13,14. Having co-evolved with the human host
for millions of years they have become highly adapted to infect and persist within the human body. The
years of this coevolution have resulted in most of the human population being infected with a herpesvirus,
even before leaving infancy; more than 90% of adults have been infected by at least one of these viruses,
with a latent form of the virus remaining in the vast majority of people. The virus is usually transmitted
through saliva15,16, blood17, organ donation18, or sexual contact19,20. These viral infections will generally
persist within the human body throughout the life of the host as a result of various mechanisms used to
evade the immune system. One of the main systems used by the virus to do this involves switching from
2

a lytic to a latent infection. Herpesviruses have the ability to actively infect and replicate in cells21, but
when the viral load has increased to a high enough level, the virus is able to convert to a latent cycle22.
This system allows the virus to bridge its genome with the human genome and stop producing viral
proteins23, giving the virus the opportunity to persist within the human host undetected. When this cycle
is active, the viral genome can be replicated along with the host cell and ultimately avoid activating any
immune response. Although the virus is able to persist within the human body throughout the life of the
host, severe disease does not usually result unless the host immune system is suppressed or compromised.
KSHV
Human herpesvirus types are classified under three subfamilies: α, β, and γ. KSHV shares many of the
same traits as others viruses within the herpesviridae family, including its fellow γ-herpesvirus, EpsteinBarr virus (EBV). This specific virus currently infects 3-10% of the U.S. population24. It is a doublestranded DNA virus that packages its genome linearly inside a protein capsid; this is surrounded by
tegument proteins and finally enclosed by a lipid envelope sequestered from the cell membrane from
which it replicates. As with other members of the HHV family, one of the more important characteristics
of this virus is the ability for KSHV to alternate between latent and lytic life cycles. In order to remain
latent within the cell the viral genome circularizes and the resultant episome is tethered to the host’s
genome via the latency-associated nuclear antigen (LANA) protein25. When the virus is ready to begin a
lytic program, the rta gene is expressed and activates other genes related to the lytic phase26. This includes
production of various virally encoded cytokines and chemokines such as vIL-6 and other inflammatory
proteins27. These proteins are imperative to disorders associated with the virus, as the resultant
inflammation increases cellular migration to the site of inflection. Subsequently the different chemokines
are able to fine-tune the types of cells that migrate to the infected cells28. This allows for tuning of the
microenvironment to avoid unfavorable cytotoxic reactions that would otherwise destroy infected or
3

damaged cells. The result is a perfect breeding ground for damaged cells to continue replicating, which
often leads to cancer.
KSHV Cancers
There are three main types of cancers associated with the KSHV herpesvirus, including classic Kaposi’s
sarcoma (KS), primary effusion lymphoma (PEL), and the plasmablastic variant of Multicentric
Castleman’s disease (MCD) 29–32. The physical manifestations of these three cancers involve lesions (the
sarcomas), lymphocyte oncogenesis, and tumors (for the MCD types).
Kaposi’s sarcoma (KS) is the classic form of KSHV-induced cancer, first found in 1872 by the Hungarian
dermatologist Moritz Kaposi6. The discovery involved the dark sarcomas found inflicting elderly male
patients in the Mediterranean33. This sarcoma is an unusual multifocal neoplasm that contains several
different cell types and is characterized by dark, purple lesions34. After this form of KS was discovered, 3
other epidemiological variants of KS were investigated: endemic, AIDS-related, and iatrogenic35, all of
which are associated with KSHV.
Classic KS was the first documented variant of the KS type, infecting mainly HIV-negative elderly
Mediterranean men. Endemic KS is a form more prevalent in mid to south Africa36; this variant is more
aggressive than the classic KS, usually affecting children37. AIDS-related KS specifically targets the
compromised immune systems of those suffering from AIDS38. Iatrogenic KS occurs after donor
recipients undergo therapy to suppress their immune system to prevent graft rejection39. KS lesions occur
throughout cutaneous as well as mucosal surfaces, lymph nodes, and visceral organs40,41. Although usually
latently infected, KSHV gene expression is found in 95% of these malignancies42, aiding diagnosis.
The second prominent cancer caused by KSHV is primary effusion lymphoma (PEL). For this particular
variant, the detection of active KSHV gene expression has become a necessary part of diagnosing this
4

type of cancer7. PEL manifests as a malignant effusion of monoclonal B cells within the peritoneal,
pleural, or pericardial space, which usually originates with the infection of B cells43. Although PEL is
commonly seen as diffused cells, a few cases of solid tumor PEL have been documented; when present,
the tumors are located in lymph node tissues44. These lymphomas make up 3% of all AIDS-related
lymphomas, the average survival time after diagnosis being 6 months45. This results from the facts that
the KSHV infection is not only very aggressive, but the treatment options relating to this rapidly fatal
cancer are extremely limited. Within PEL, KSHV remains largely latent, but a large genome copy number
exists within the cell (50-150 copies)46. The latency of the infection implies that a minimal number of
proteins are actively expressed. During the latency phase, very few proteins are produced, one of which
is vIL-6 (to be explained in the next section); 2–5% of PEL cells actively express this protein47. Associated
with the production of these viral cytokine proteins, KSHV-infected B cells are also seen to display
mutated immunoglobulin genes, and late-stage B cell markers such as (CD30 and CD138)48. This leads
us to believe that these cells originated from post-germinal centers. Observing and understanding these
characteristics is imperative in creating new targets for cancer treatment, and add more information to the
study of this aggressive cancer.
A third cancer associated with KSHV is plasmablastic multicentric Castleman’s disease (MCD). This is
characterized by localized B cell proliferation and vascular proliferation in germinal centers, usually
forming a solid tumor mass following KSHV infection. The virus is reported to be found within all HIVpositive MCD cases, as well as 40% of HIV-negative cases49–51. It is most commonly seen in AIDS
patients and transplant recipients due to the repressed immune systems of both. Similar to the PEL variant,
5–25% of infected cells express vIL-6 in MCD tumors and generally appear to have a higher number of
productive KSHV infected cells than that of PEL52. The polyclonal plasmablastic form of MCD is
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extremely aggressive in those co-infected with HIV53,54, the progression of which is thought to be caused
by the imbalance of cytokines such as IL-6, IL-12, and VEGF55–58.
Due to the limited insights into the KSHV infections, there are few options with which to treat them;
clinicians typically use monoclonal antibodies to target B cells for destruction, but this method is not
specific to tumor cells. This research hopes to investigate new relationships between cytokines produced
by the virus and cancer development, which could potentially lead to a targeted treatment option.
Viral Interleukin-6 (vIL-6)
Similar to other herpesviruses, KSHV has managed to pirate various human genes into its own genome as
it has evolved alongside its host. One of these homologs is viral interleukin-6 (vIL-6). This cytokine is
actively produced within many KSHV-associated malignancies59,60, with the highest levels detected in
MCD patients51. The vIL-6 cytokine is encoded in ORF K2 of the KSHV genome. The protein shares a
25% amino acid identity with its homolog, human IL-6 (hIL-6), or in a 63% amino acid similarity61–63.
This indicates that there have been changes made to the gene throughout the history of the virus; leading
us to assume that some functions of the protein may have been adjusted.
Within the human body, the IL-6 protein is used as a proinflammatory cytokine, gp130 signal enhancer,
B cell proliferator, as well as an anti-inflammatory agent during muscle contraction 64. hIL-6 influences
target cells by binding its IL-6 receptor (also known as gp80), as well as two transmembrane glycoproteins
(gp130 homodimer)65. Once this new complex has formed, dimerization leads to the activation of various
signaling cascades. One of the most understood of these pathways is that of Janus kinas (Jak)3/STAT
pathway66. This signaling pathway is associated with various information transfers from outside of the
cell to the cell nucleus, resulting in transcription and expression of genes for processes including
differentiation, apoptosis and oncogenesis.
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To control these pathways vIL-6 uses different methods than hIL-6. Although it is necessary for hIL-6 to
bind both IL-6R and gp130 in order to trigger a signal cascade, this is not the case with vIL-6. It is not
required for vIL-6 to bind both the gp130 subunit and the IL-6 receptor in order to activate cell signaling67–
69

, but when gp130 is bound, the signaling is enhanced70,71. This indicates an ability for the virally

produced cytokine to use whatever complex is available to activate signaling pathways. This may seem
like a significant alteration between the hIL-6 and vIL-6, but it has been shown that vIL-6-gp130 binding
is ~1000-fold lower than the hIL-6, IL-6R, and gp130 binding complex; making it less efficient as an
extracellular cytokine than hIL-647. This indicates a loss of productivity to the protein when using this
adjusted function.
Furthermore, although it seems that vIL-6 has some advantages in terms of the potential to stimulate gene
expression in the absence of the IL-6 receptor, its secretion from the cell is less efficient than hIL-6. It has
been seen that most vIL-6 remains localized in the endoplasmic reticulum (ER)72,73; but with the help of
gp130, the protein can be released into the rest of the cell74. vIL-6 will not remain sequestered indefinitely,
as the death of KSHV-infected cells could potentially trigger a substantial dump of vIL-6 into the
surrounding tissue75. These occasional bursts of vIL-6 could be due to active viral replication or cytotoxic
T cell killing of infected cells. These different distributions of vIL-6 still result in the induction of cellular
IL-6 expression into several cell-types76, which goes on to play a role in the pathogenesis of KSHV.
Past research has also shown that host-encoded IL-6 is imperative in phenotypes associated with
symptomatic KSHV infections. A study was performed on the transgenic expression of vIL-6 in mice,
which resulted in hyperplastic germinal centers in the lymph nodes, plasmacytosis in the spleen, and other
MCD-like phenotypes. These observations were absent in the IL-6 knock-out mice, leading us to conclude
that mammalian IL-6 is essential to the mechanisms of vIL-6 during infection 77. Such conclusions begin
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to build a picture of a dynamic and potentially complex role for vIL-6 in the oncogenic process that we
hope to begin to unravel.
vIL-6 is expressed during both lytic and latent KSHV infections, which is unusual for virally produced
cytokines. The fact that this protein is utilized throughout both types of life cycles indicates some
important roles potentially associated with this protein. Some of these roles potentially involve the
activation of similar signaling pathways to those triggered by the human IL-6 counterpart, such as
JAK/STAT, MAPK, and PI3K/Akt pathways (Figure 1)78,79. These pathways lead to the upregulation of
hIL-676, VEGF, B cell proliferation, and other cytokines (IL-10 and IL-12) 47,80,81. It has been shown that
in vivo, vIL-6 increases angiogenesis of tumors via VEGF (Figure 1), a growth factor known to increase
angiogenesis and endothelial cell invasion82,83. Increased vascularization would allow tumor cells to
remain more viable and provide the virus a greater access to the environment around the tumor. B cell
proliferation is also advantageous to the virus, as the virus primarily infects B lymphocytes. This allows
the virus to access a larger population of cells to infect and subsequently replicate within.
The purpose of this project is to further understand the role of vIL-6 in Kaposi’s sarcoma herpesvirus
(KSHV) tumor development. Viral interleukin 6 is currently thought to aid tumor growth by upregulating
proteins which promote angiogenesis, B cell proliferation, and anti-apoptosis signals 72. Our hypothesis
is that viral interleukin-6 is necessary for tumor development in larger tumors such as those found in
MCD; therefore, when present, it is expected to increase tumor mass and promote angiogenesis as well
as metastasis of the tumor. The hypothesis was tested by injecting B cells that are latently infected with
KSHV into highly immunocompromised mice in order to analyze the effects of vIL-6 on tumor
development. The technique of injecting KSHV-infected B cells both subcutaneously and into the
intraperitoneal has been previously shown to produce tumors 80. By comparing tumors induced by KSHV,
with and without the gene for vIL-6, it is possible to identify whether vIL-6 could be an effective target
8

for treating KSHV induced cancers. Not only does this thesis compare the physical characteristics of both
tumors, such as mass, and total number of tumors, but it measures different cell marker levels which may
indicate any effects that vIL-6 plays in tumor growth and development. Since classic Kaposi’s sarcoma
infections are cancers of the endothelial cells, we are unable to mimic this type of infection within a mouse
model. Hence the investigation focuses on the role of vIL-6 in KSHV infections similar to PEL and MCD
cancers.

9

Figure 1. The JAK/STAT signaling pathway. This pathway can be stimulated by IL-6 using either the gp130 or
the gp130-IL-6-complex (Source: KSHV: pathways to tumorigenesis and persistent infection by Giffin &
Damania79).

10

Materials and Methods
As described above, the purpose of the experimental procedure is to determine the influence of vIL-6 on
KSHV induced tumor development. Various stages characterized the process of tumor formation and
analysis. Healthy cell lines were infected with the desired viruses and cultivated. Mice were then injected
subcutaneously over the abdomen with the different cell types, and tumors were allowed to develop for 5
weeks. Tumors were then extracted and analyzed for mass and frequency before phenotypes were
documented via flow cytometry.
A. Cells and viruses
i.

Cell types used

The desired virus and cells (BJAB, BJAB WT, and BJAB ΔvIL-6) were all supplied by Dr. Lagunoff
(University of Washington). The first group of cells (BJAB) is simply the uninfected immortalized B cell
line. The second group of cells (BJAB WT) included the KSHV wild-type virus. The virus is in the human
B cell line, BJAB, in the form of a BAC construct containing the KSHV genome, GFP, and a puromycin
resistance gene84. The last group of cells (BJAB ΔvIL-6) contained a BAC constructed with a KSHV
genome with 303 bases of the pKS11K2 vIL-6 reading frame removed by digesting EcoRI and PstI85,
GFP, and a puromycin resistance gene. All cells were recovered by defrosting the pre-frozen samples
before adding 14mL of PBS in order to dilute the dimethyl sulfoxide (DMSO) that is used to protect the
cells during the freezing process. This was then centrifuged at 3,000rpm for 3 minutes and the supernatant
discarded. The cells were then grown in RPMI 1640 containing 10% fetal bovine serum (FBS), 100x
penicillin/streptomycin, 2mM L-glutamine, and sodium bicarbonate. After mixing this solution the pH
was adjusted to 7-7.2 to provide an ideal cell growth environment. The solution was filter-sterilized and
warmed to 37°C before adding cells. Cells were seeded at a density of ~500,000 cells/mL; lower densities
would keep the cells from thriving within the media. Cells were then be incubated at 37°C, 5% CO2. After
11

allowing the cells to revive and begin growth within the media for over 24hrs we added a 1:100 dilution
of 10mg/mL puromycin to the RPMI media of both solutions of virally-infected cells and passaged for
one month to select for puromycin-resistant GFP+ cells. We maintained healthy stocks of BJAB, BJAB
with wild-type KSHV, and BJAB with KSHV ΔvIL-6 cells until 80% of virally-infected cells were GFP+
(as confirmed using flow cytometry).
ii.

Cell verification

Before injection all cell types were stained with propidium iodide in order to assess the percentage of live
and dead cells. GFP positive cells were monitored and selected for until at least 80% of cells expressed
the gene.
B. Mouse injections
It had been previously shown that injection of 5x106 KSHV-infected B cells causes visible tumors via
subcutaneous injection in 2 out of 3 SCID mice 80. We decided to use the more immune-deficient Balb/c
Rag2-/- γc -/- mouse strain so as to guarantee tumor development. Once the cells were grown to the desired
concentration, 5x106 live cells from each group were centrifuged and re-suspended in 40μL of Iscove's
Modified Dulbecco's Medium (IMDM). Using a BD 28 – gauge needle, each mouse, aged between 8-15
weeks old, was injected subcutaneously, directly over the abdomen. The needle remained in place for 30
seconds after injection, and was slowly removed (10s). An initial 6 mice per study group were used, 3
males and 3 females; the experiment was then repeated, resulting in 12 mice per study group, and a total
of 36 mice. Animals were monitored for changes in health for 5 weeks.
Hazards throughout the process were minimized by using standard procedures and IACUC protocols. The
BYU Institutional Animal Care and Use Committee approved our proposal to begin this research (protocol
# 15-0108).
12

C. Histology
i.

Harvesting tumors

After 5 weeks tumors were identified and the animals were sacrificed consistent with recommendations
from the Panel on Euthanasia of the American Veterinary Medical Association. Mice were dissected and
the tumors excised. The total number of tumors, as well as individual and total tumor mass per animal
were recorded. Tumors were then cut in two. One of half of each tumor per mouse was placed flat in a
plastic mold before being covered with optimum cutting temperature (O.C.T) compound (Tissue-Tek
Fischer Medical Company) and stored at -80°C. The rest of the tumors were separated into individual cells
using a plunger from a 10mL syringe (BD), 1 X PBS, and a 40μm Cell Strainer (BiolGix Research
Company). These cells were then set aside for flow cytometry.
ii.

Slide preparation

Tumor tissue samples were prepared for staining by using the Microm HM550 to mount 12μm tumor
sections onto Superfrost Plus, positively charged white slides (Thermo Scientific). O.C.T covered tumors
were removed from -80°C and the blocks mounted at -21°C using more O.C.T compound. These were
then left for a minimum of 20 minutes to allow the tissue sample to reach a stable temperature. The sections
were then cut at -19°C to a thickness of 12m before mounting onto the slide. These samples were left to
fix at room temperature for 30 minutes before storing long-term at -80°C.
D. Flow cytometry
In order to analyze the expression profiles of both cultured cells and those extracted from the tumors,
200,000 live cells were counted and collected using a hemocytometer, the supernatant removed, and the
cells re-suspended in 100μL of FACS stain buffer. 3μL of Mouse/Human Fc block was added and
incubated at 4°C for 15 minutes. 3μL of the desired antibody was added and incubated for 30 minutes at
4°C. The cells were then fixed by adding 1% paraformaldehyde up to 500μL. The cells were then
13

centrifuged for 3 minutes at 3,000rpm, the supernatant removed, and the cells re-suspended in 500μL of
1X PBS. Due to the different light frequency requirements of the antibodies used, it was necessary to run
the analysis via 2 panels. Panel A: CD45 (PE-cy7), CD19 (APC-e-Fluor780), CD20 (APC), CD138 (PEcy5.5), CD22 (PE). Panel B: CD19 (APC-eFluor780), CD38 (PE-cy7), CD30 (APC). Unstained controls
of both BJAB and BJAB KSHV WT cells were also analyzed for contrast with the stained cells.
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Chapter 1
Results
No suitable animal study has extensively investigated the behavior of vIL-6 in regards to tumor
development in vivo. Previous research has proved that injected BCBL-1 cells, harboring latent KSHV
into Rag2-/-γc-/- mice, results in the development of vascularized tumors; similar results were expected
here with different KSHV strains80. Physical characteristics of tumors grown in the presence or absence
of vIL-6, as well as investigations into gene expression that could be affected by vIL-6 were assessed after
tumor formation.
The hypothesis underlying this thesis is that the presence of vIL-6 will promote growth of tumors. In fact,
the results of the tests on the twelve mice demonstrated no statistically significant difference in the tumor
rate of growth. The detailed results are summarized below, and the potential causes are analyzed in the
context of expression profiles measured for each cell type.
Analysis of number and mass of tumors extracted
As outlined in the methods section, cells with and without the vIL-6 were grown in culture until both
populations showed 80% or more GFP expression. The Balb/c Rag2-/- γc -/- mice were then injected with
5x106 live cells from each group of cultured cells, subcutaneously, directly over the abdomen. The mice
were monitored for 5 weeks before the tumors were extracted, analyzed, and further FACS
experimentation performed on the cells derived from the tumors. All tumors of visible size were removed;
most often these were easily extracted from the intraperitoneal space using tweezers, although some had
formed subcutaneously, and required surgical removal before analysis.
The mass of each tumor was recorded, and an assessment was made of the significance of any variation
in tumor growth between the two cases. In general, the mice injected with the cells that contained vIL-6
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(KSHV WT) had more tumors (up to a maximum number of 4) but of lower average mass than those from
the mice with the protein deficient cells. This potential difference in tumor behavior is highlighted in a
comparison of total mass and number of tumors in order to determine basic tumorigenesis of cells infected
with KSHV with and without the vIL-6 gene.
Statistical analysis of this behavior found no significant difference between the number of tumors or the
mass of tumors when comparing ΔvIL-6-infected mice and WT-infected mice (Figure 2 & Figure 3).
However, WT-infected mice clearly exhibit a higher average number of tumors (Figure 2), by 1.538
tumors; the statistics are within 1% of statistical significance according to the typical 95 percentile analysis
(p=0.0592).
Given that a more significant difference in response was predicted for the different mice, in order to
explore the reasons behind this unexpected finding, a more detailed analysis of the expression profiles
from the various cell types was undertaken. Seven cell markers were quantified, with particular focus on
the CD30 marker to determine the potential influence of these factors on the results. Cells in the following
categories were investigated and compared:
1. Cells with and without vIL-6 grown in culture (KSHV WT vs KSHV ΔvIL-6)
2. KSHV WT-infected cells before and after tumor development
3. KSHV ΔvIL-6-infected cells before and after tumor development
4. Cells with and without vIL-6 after tumor growth (KSHV WT vs KSHV ΔvIL-6)
Comparison of expression profiles for KSHV ΔvIL-6 and KSHV WT cells grown in culture
Differences in gene expression patterns between constructs containing KSHV with an intact vIL-6 gene
(KSHV WT) vs those with a deleted vIL-6 gene (KSHV ΔvIL-6) were cataloged using flow cytometry.
BJAB cell populations grown in culture were analyzed in order to determine any differences before
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infecting the mice with KSHV, and we later performed similar experiments comparing cells extracted
from tumors that developed inside of mice. We used the profiles taken of cultured cells and compared
them to those that were extracted from tumors in order to determine if changes in gene expression took
place during the process of tumor development.
Most experiments were directed at B cell markers because our BJAB construct is a human B cell line.
GFP expression (viral constructs contain the GFP gene) also allowed verification that similar percentages
of cells were infected with KSHV before the mice were infected (Figure 4).
Data on the seven quantified markers (Figure 5A) indicated several statistically significant observations.
KSHV ΔvIL-6-infected BJAB cells displayed 7.7% more CD45+GFP+ (p <0.0001); 3.6% more
CD45+CD22+ (p=0.0098); and 8.2% more CD45+CD138+ expressing cells (p=0.0002) compared with
KSHV WT-infected cells.
This dataset provided a baseline for comparison of these cell lines after tumor growth. The analysis shows
that certain genes were expressed differently in cells depending upon the presence or absence of the vIL6 gene. We then re-analyzed our results to examine the mean fluorescence intensity (MFI) of different
cell surface markers. MFI measures the intensity of antibody binding to cellular markers, and so in
addition to determining if a gene was expressed or not (Figure 2A) we also examined if genes were
expressed at different levels by measuring the MFI (Figure 5B & Figure 6).
We found that the MFI (Figure 5B) of these populations showed a lower intensity in KSHV WT-infected
BJAB cells compared with uninfected BJAB cells in CD45+GFP+ markers and CD45+CD22+ markers.
The differences being 2.6x104 lower GFP (p <0.0001) and 1.1x103 lower CD22 (p <0.0001).
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Comparing expression profiles of KSHV WT-infected cells grown in culture vs those extracted from
tumors
Deviations from the initial profiles of KSHV WT-infected BJAB cells as a result of tumor growth were
analyzed using FACS analysis. Cultured KSHV-infected cells contained higher frequencies (Figure 7A)
of CD45+ markers; CD45+GFP+ markers; CD45+CD19+ markers; CD45+CD20+ markers;
CD45+CD22+ markers; and CD45+CD138+ markers compared with cells collected from tumors of
KSHV-infected mice. CD45 had a 12.40% decrease (p <0.0001), GFP a 52.33% decrease (p <0.0001),
CD20 a 27.41% decrease (p=0.0009), CD22 a 36.56% decrease (p <0.0001), and CD138 a 10.47%
decrease (p <0.0001) in tumor cells. CD45+CD30+ expression was upregulated in KSHV-infected tumor
cells by 13.66% (p <0.0001). There are a significant number of decreased markers following tumor growth
in the case of KSHV WT-infected cells, with the percent of CD30+ cells increasing.
Mean fluorescence intensity of cultured KSHV WT-infected cells (Figure 7B) showed higher intensities
for CD45 markers by 7.7x104 (p <0.0001); CD45+GFP+ by 9.3x104 (p <0.0001); CD45-GFP+ by 4.3x104
(p=0.0006); CD45+CD19+ markers by 4.6x104 (p <0.0001); CD45+CD20+ markers by 4.4x104 (p
<0.0001); CD45+CD22+ markers by 1.4x103 (p <0.0001); and CD45+CD30+ markers by 1.6x104
(p=0.0127) compared with KSHV-infected tumor cells. The MFI of most markers show a significant
decrease in intensity post tumor-development.
Comparing expression profiles of KSHV ΔvIL-6-infected cells grown in culture vs those extracted
from tumors
After the tumors developed and cells extracted, we were capable of analyzing any differences that occurred
to the expression profiles of ΔvIL-6-infected cells due to tumor growth, based upon the baseline
established in the previous section.

18

Figure 8A captures the relevant data, with significant results as follows: KSHV ΔvIL-6-infected cultures

showed increases in frequency of CD45+ populations by 20.65% (p <0.0001); CD45+GFP+ markers by
56.93% (p <0.0001); CD45+CD19+ markers by 0.43% (p=0.0117); CD45+CD20+ markers by 27.95%(p
<0.0001); CD45+CD22+ markers by 39.03%(p <0.0001); and CD45+CD138+ markers by 13.54%
(p=0.0111) compared with uninfected BJAB cells. CD45-GFP+ markers increased by 6.062% (p=0.0244)
and CD45+CD30+ markers increased by 35.28% (p=0.0003) in KSHV ΔvIL-6-infected tumor cells. One
significant observation that can be made is that most markers decrease in quantity after tumor growth;
however, this is not true of the CD30 marker, which actually increases in frequency. This is particularly
meaningful due to the potential correlation between CD30 presence and cancer growth highlighted by
other researchers.
Figure 8B displays the mean fluorescence intensity of the various markers. Cultured BJAB cells showed

higher intensities for CD45+ populations by 6.3x104 (p <0.0001); CD45+GFP+ markers by 1.2x105 (p
<0.0001); CD45-GFP+ markers by 5.7x104 (p=0.0033); CD45+CD19+ markers by 4.7x104 (p <0.0001);
and CD45+CD20+ markers by 4.1x104 (p <0.0001) compared with uninfected BJAB cells. These results
reinforce the general trend for reduction in marker presence for most markers. For CD30, the intensity has
remained fairly constant, while the frequency has increased (as shown in the previous figure).
Comparing expression profiles of KSHV ΔvIL-6 and KSHV WT cells extracted from tumors
Differences in the expression profiles of cells infected with and without vIL-6 were expected. It was hoped
that further analysis would explain the results of the significance found during the preliminary tumor
analysis, as well as the general oncogenic mechanism of KSHV. Figure 9A displays the experimental data
of marker frequencies found for KSHV WT and ΔvIL-6 populations after tumor development, the
significant findings of which are summarized: KSHV ΔvIL-6-infected tumor cells were seen to have
increased live (propidium iodine negative) GFP+ and live CD30+ markers by 20.54% (p=0.0442) and
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10.12% (p=0.0110) respectively compared to the KSHV WT infection. KSHV WT-infected tumor cells
showed a higher frequency of CD45+ populations by 8.717% compared with KSHV ΔvIL-6-infected
tumor cells (p=0.0206).
Mean fluorescence intensity of these populations showed, in Figure 9B, a lower intensity in KSHV WTinfected tumor cells compared with KSHV ΔvIL-6-infected tumor cells in live CD30+ markers by 1.5x103
(p=0.0485). This further verifies the decrease of CD30 seen in the previous finding.
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Figure 2. vIL-6 affects the number of tumors derived from KSHV-infected mice outside of 95% confidence.
Each tumor was carefully excised from the mice and numbered at 5 weeks. The total number of tumors in each
mouse from both groups was then analyzed (n=12, n=11).
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Figure 3. vIL6 does not affect the mass of tumors in KSHV-infected mice. Each tumor was carefully excised
from the mice and weighed at 5 weeks. The total weight of each group was then analyzed (n=12, n=11).
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Figure 4. FACS analysis of propidium iodide negative, GFP+, CD30+ populations. Experiments were first

gated on PI- markers, these PI- cells were then gated for GFP+ markers, finally PI-, GFP+ cells were gated for
CD30+ markers and the results analyzed (this process was repeated for CD45+ populations that were analyzed.).
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Figure 5. FACS analysis comparison of cultured KSHV ΔvIL-6 –infected BJAB cells and KSHV WT-infected
BJAB cells. A, Frequency of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30;
B, Mean fluorescence intensity of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and
CD30. (* indicates a statistical significance less than p = 0.05 according to a pooled t-test analysis)
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Figure 6. Histogram of the CD30+ population comparing KSHV WT and KSHV ΔvIL-6. Overlay of CD30+
populations from mean KSHV WT and KSHV ΔvIL-6-infected tumor cells.
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Figure 7. FACS analysis comparison of cultured KSHV WT-infected BJAB cells and those extracted from
tumors. A, Frequency of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30;
B, Mean fluorescence intensity of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and
CD30. (* indicates a statistical significance less than p = 0.05 according to a pooled t-test analysis)
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Figure 8. FACS analysis comparison of cultured KSHV ΔvIL-6-infected BJAB cells and those extracted from
tumors. A, Frequency of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30;
B, Mean fluorescence intensity of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and
CD30. (* indicates a statistical significance less than p = 0.05 according to a pooled t-test analysis)
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Figure 9. FACS analysis comparison of KSHV ΔvIL-6 –infected BJAB cells and KSHV WT-infected BJAB
cells extracted from tumors. A, Frequency of CD45+ and propidium iodine-negative populations, which display
markers for GFP, CD19, CD20, CD22, CD138, and CD30; B, Mean fluorescence intensity of CD45+ cells, which
display markers for GFP, CD19, CD20, CD22, CD138, and CD30. (* indicates a statistical significance less than p
= 0.05 according to a pooled t-test analysis)
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Discussion
The initial hypothesis proposed that the highest number of tumors and highest tumor mass should exist in
the wild-type KSHV infected mice. This was based upon an extrapolation from previous research that
showed an increase of blood flow due to the vIL-6 protein; hence feeding tumor growth via viral
interleukin-6 being present throughout the tumor development. In contrast, it was expected that fewer and
smaller tumors would occur within those mice infected with the mutant virus, due to the lack of vIL-6.
Tumor Analysis
From Figure 2, it is clear that more tumors are produced in the cells with the vIL-6 protein. When analyzed
using a pooled T-test, the difference in number of tumors was outside of the margin for statistical
significance (the calculated p-value was 0.059, while a statistically significant value would be below 0.05).
Hence, while the number of tumors produced by KSHV WT-infected cells and KSHV ΔvIL-6-infected
cells was not categorically significant using this particular statistical metric, the p-value was close to
significant, leading us to believe that further investigation and more test subjects would potentially
demonstrate that there is in fact a statistical correlation between the presence of the protein and the number
of tumors that are produced.
However, from Figure 3, it is clear that the total mass of tumor has not significantly changed due to the
presence or lack of the protein; i.e. vIL-6 does not assist in creating larger tumors. This indicates that vIL6 may contribute to different stages of cancer progression in different ways. Models for cancer categorize
the development of the ailment into various phases; the two relating most to our analysis being onset and
progression86. With this in mind, vIL-6 could be playing a prominent role in the onset of cancer – helping
tumors initiate – as opposed to supporting the progression and subsequently increasing mass of the tumor.
The combination of results indicates that vIL-6 potentially increases metastasis in WT KSHV versus
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ΔvIL-6 KSHV, indicating that vIL-6 potentially increases the spread of KSHV throughout the body,
increasing cancerous tumors within the host, but does not promote growth of the metastasized tumors.
While this result was weaker than desired, based upon the initial hypothesis, it only provides one view of
the tumor growth process, at the macroscopic level. A more in-depth analysis of tumor development at
the cell level is possible via quantification of markers associated with the cancer cells from each
experiment. The markers that we examined included: CD19+, a B cell marker; CD20+, a B cell marker
that aids in differentiation into plasma cells; CD22+, a regulatory molecule of B cell interactions and a
marker of memory B cells; CD30+, a TNF receptor superfamily member that can mediate signal
transduction events that can stimulates proliferation or initiate apoptotic cell death pathway; CD45+, a
leukocyte marker that aids in regulating cell growth and differentiation; and CD138+, a plasma cell marker
which aids in cell proliferation and migration87. A brief discussion of the results of this study, for the
various experiments, are given in the following sections.
Impact of KSHV ΔvIL-6 gene on human B cell markers in culture
The baseline picture of marker presence in the original B cells was provided by the initial phenotypic
analysis of both KSHV WT cells and KSHV ΔvIL-6 cells within culture before injection into the mice.
This uncovered patterns present within these cells before tumor growth. Higher GFP+, CD22+, and
CD138+ expression was seen in cells without vIL-6. We can assume that these differences are due to the
selection process made during the development of both of these virally-infected B cells.
Impact of vIL-6 on B cell makers in both KSHV ΔvIL-6 and KSHV WT-infected cells after tumor
development
After excising the tumors, the profiles of the two cell groups were evaluated after tumor development.
When comparing each group of cells before and after infection we see that, generally, expression decreases
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in vivo vs. in vitro - except in the case of CD30+ cells, which increase. This trend of decreasing markers
can be explained through the common phenomenon of cell de-differentiation throughout cancer
development.
Cellular differentiation is the process whereby a cell changes from one cell type to another in order to
specialize in a specific function88. Conversely, de-differentiation is a phenomenon seen throughout the
conversion of a normal cell into an oncogenic one. These cells become less specialized as they revert to
an earlier developmental stage to survive. Two major nonexclusive hypotheses of the cellular origin of
cancer are that malignancy arises from either stem cells experiencing maturation arrest or dedifferentiation of mature cells that retain the ability to proliferate89.
A common theme exhibited in both strains is the increase in CD30+ cells after tumorigenesis. A tumor
necrosis factor, CD30 (or TNFRSF8) is a cell membrane protein found on activated T and B cells90.
Stimulation of CD30 has been shown to lead to proliferation as well as apoptotic death91. This information
supports the selection of oncogenic cells amongst KSHV-infected B cells.
Impact of KSHV ΔvIL-6 gene on human B cell markers in cells extracted from tumors
When the expression profiles were compared between both KSHV WT and KSHV ΔvIL-6-infected cells,
after tumor growth, there were several significant differences. KSHV WT-infected cells showed an
increase in CD45+, but a decrease in live cells with GFP+ and CD30+ markers. This may be due to the
selection process made during the construction of the KSHV-infected BJAB cells, as GFP+ cells were
decreased in KSHV WT-infected cells compared with KSHV ΔvIL-6-infected cells before tumor growth.
Cells containing vIL-6 express much less CD30 compared with those cells without vIL-6 after tumor
growth, which may indicate that vIL-6 helps control CD30 expression. This would be advantageous to the
virus in order to postpone detection as an oncogenic cell within the host. This, in turn, may allow for a
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higher spread of the virus – which merits further investigation with an increased subject size to determine
the significance in the difference in number of tumors developed between strains.
Summary
From this study we see various roles that vIL-6 could be playing within tumor development. One of these
functions being that vIL-6 appears to increase the number, but not overall mass, of tumors. This indicates
that vIL-6 increases the spread of cancer within the infected host, but not necessarily tumor growth. We
also see that although CD30 increases in vivo compared to cultured cells, it appears that vIL-6 inhibits the
frequency of CD30 relative to the mutant cells that did not contain vIL-6. Further investigation into how
CD30 affects cancer development is needed before any conclusions can be made as to whether the vIL6
protein could potentially be used as a target for cancer treatment in the future.
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Chapter 2
Results
While the initial study reported in the previous chapter focused on the presence and absence of the vIL-6
protein in the injected B cells, a second control experiment was undertaken using uninfected BJAB cells.
This study compared the tumor progression with and without the KSHV virus. The expectation was that
BJAB cells would not promote tumor development due to their lack of oncogenic viral infection.
Preliminary findings suggested that this was not the case, so a more in-depth study was undertaken. This
chapter presents the results of this investigation.
Tumor Analysis
As described in previous sections, tumors were harvested from Balb/c Rag2-/- γc -/- mice 5 weeks after
they were injected with 5x106 live cells from each group of cultured cells subcutaneously, directly over
the abdomen. As for the experiment described in the previous chapter, the mass of each tumor was
recorded, and the overall mass and number of tumors was analyzed.
In this particular case, there was no significant difference (p=0.73) between the number of tumors in
BJAB-injected mice and WT-KSHV-injected mice (Figure 10); both cell types resulted in more tumors
than the KSHV vIL-6 mutant virus. However, BJAB-injected mice exhibited tumors of significantly larger
mass (Figure 11); the average tumor mass is more than double that of WT-injected mice, resulting in a
statistical significance given by p=0.040.
Once again, the reasoning behind this difference in behavior for the two cell types is not immediately
clear. Hence a more detailed study of the expression profiles was once again undertaken, as summarized
in the next few sections. As before, cell markers associated with the following experiments are contrasted
and compared.
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1. Cells with and without KSHV grown in culture (uninfected BJAB vs KSHV WT-infected BJAB)
2. Uninfected BJAB cells before and after tumor development
3. KSHV WT-infected cells before and after tumor development
4. Cells with and without KSHV after tumor growth (uninfected BJAB vs KSHV WT-infected
BJAB)
Comparison of expression profiles for uninfected immortalized BJAB cells and KSHV WT-infected
BJAB cells in culture
Differences in gene expression patterns between our immortalized BJAB cell line and the BJAB construct
containing KSHV were cataloged using flow cytometry. BJAB cell populations grown in culture were
analyzed in order to determine any differences before infecting the mice with immortalized B cells with
and without KSHV. We later performed similar experiments comparing cells extracted from tumors that
developed inside of mice. The profiles taken of cultured cells were compared with those that were
extracted from tumors in order to determine if changes in gene expression took place during the process
of tumor development due to the presence of KSHV.
Most experiments were directed at B cell markers because our BJAB construct is a human B cell line.
GFP expression (viral constructs contain the GFP gene) also allowed verification of a KSHV-infection
within BJAB cells before the mice were injected (Figure 4).
Looking at the frequency of markers (Figure 12A) it can be seen that KSHV WT-infected BJAB cells
displayed 8.83% more CD45+ (p <0.0001) and 2.857% more CD45+CD20+ (p=0.0192) expressing cells
than uninfected immortalized B cells. KSHV -infected BJAB cells were also seen to downregulate
CD45+CD22+ markers by 30.13% compared to uninfected BJAB cells (p <0.0001).
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As before, this dataset provided a baseline for comparison with the other experimental conditions, and
indicated that certain genes were expressed differently in cells depending upon the presence or absence of
KSHV. The cells were then re-analyzed to examine the mean fluorescence intensity (MFI) of different
cell surface markers. MFI measures the intensity of antibody binding to cellular markers, and so in
addition to determining if a gene was expressed or not (Figure 10A) we also examined if genes were
expressed at different levels by measuring the MFI (Figure 12B & Figure 6).
Mean fluorescence intensity of these populations (Figure 12) showed a lower intensity in KSHV-infected
BJAB cells compared with uninfected BJAB cells in CD45+CD19+ markers; CD45+CD22+ markers; and
CD45+CD138+ markers. The differences being 1.7x104 lower CD45+CD19+ (p=0.0342), 5.1x103 lower
CD45+CD22+(p <0.0001), and 1.2x103 lower CD45+CD138+ (p=0.0180) in KSHV-infected BJAB cells
compared with uninfected BJAB cells.
Comparing expression profiles of immortalized BJAB cells grown in culture vs those extracted from
tumors
Changes to the expression profiles of the immortalized B cells were explored following our preliminary
tumor analysis, so as to explore anomalies made to the baseline documented in the previous section due
to tumor growth.
Immortalized BJAB cultures showed increases in frequency (Figure 13A) of CD45+CD20+ markers by
23.41% (p=0.0003); CD45+CD22+ markers by 65.88% (p <0.0001); and CD45+CD138+ markers by
12.28% (p=0.0042) compared with uninfected BJAB. BJAB cells found in the tumors of injected mice
upregulated CD45+CD30+ markers 17.34% compared with BJAB cells grown in culture (p=0.0059). A
trend of decreased cellular markers following tumor development is exhibited in most markers except that
of CD30.
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Mean fluorescence intensity of cultured BJAB cells (Figure 13B) showed higher intensities for CD45+
markers by 8.1x104 (p <0.0001); CD45+CD19+ markers by 5.4x104 (p <0.0001); CD45+CD20+ markers
by 3.4x104 (p <0.0001); CD45+CD22+ markers by 5.8x103 (p <0.0001); and CD45+CD30+ markers by
1.4x104 (p=0.0315) compared with BJAB tumors of injected mice. The results of the intensities shown
establish the decrease of cellular markers, even in that of CD30.
Comparing expression profiles of KSHV WT-infected cells grown in culture vs those extracted from
tumors
As mentioned in the previous chapter, deviations to the initial profiles of KSHV WT-infected BJAB cells
as a result of tumor growth were also analyzed using flow cytometry. Cultured KSHV-infected cells
contained higher frequencies (Figure 7A) of CD45 markers; CD45+GFP+ markers; CD45+CD19+
markers; CD45+CD20+ markers; CD45+CD22+ markers; and CD45+CD138+ markers compared with
cells collected from tumors of KSHV-injected mice. CD45+ having a 12.40% decrease (p <0.0001),
CD45+GFP+ a 52.33% decrease (p <0.0001), CD45+CD20+ a 27.41% decrease (p=0.0009),
CD45+CD22+ a 36.56% decrease (p <0.0001), and CD45+CD138+ a 10.47% decrease (p <0.0001) in
tumor cells compared with cultured cells. CD45+CD30+ expression was upregulated in KSHV-infected
tumor cells by 13.66% (p <0.0001). There are a significant number of decreased markers following tumor
growth in the case of KSHV WT-infected cells. CD45+CD30+ cells are shown to again increase.
Mean fluorescence intensity of cultured KSHV WT-infected cells (Figure 7B) showed higher intensities
for CD45+ markers by 7.7x104 (p <0.0001); CD45+GFP+ by 9.3x104 (p <0.0001); CD45-GFP+ by
4.3x104 (p=0.0006); CD45+CD19+ markers by 4.6x104 (p <0.0001); CD45+CD20+ markers by 4.4x104
(p <0.0001); CD45+CD22+ markers by 1.4x103 (p <0.0001); and CD45+CD30+ markers by 1.6x104
(p=0.0127) compared with KSHV-infected tumor cells. The MFI of most markers show a significant
decrease in intensity when comparing cells post tumor-development vs. pre tumor-development.
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Comparing expression profiles of uninfected BJAB cells and KSHV WT-infected BJAB cells
extracted from tumors
Differences in the expression profiles of immortalized B cells and KSHV-infected B cells were again
analyzed following the preliminary tumor analysis in order to expound on our findings. We hoped that a
more in-depth explanation of our significant results could be garnered through FACS analysis.
When we looked at the frequencies of uninfected and KSHV-infected tumor cells (Figure 14A) we saw
that KSHV-infected tumor cells downregulated live CD30+ markers by 9.057% in vivo compared to the
uninfected BJAB infection (p=0.0358). This confirmed a higher number of CD30+ cells in uninfected
BJAB tumors compared with KSHV-infected tumors.
Mean fluorescence intensity of these populations (Figure 14B) showed a lower intensity in KSHV-infected
BJAB cells compared with uninfected BJAB cells in CD45+CD20+ markers and live CD30+ markers.
The differences being 1.1x104 lower CD20 (p=0.0271), and 2.8x103 lower CD30 (p=0.0037). A
discrepancy in CD30 markers between the two cell groups was confirmed by the lower intensity of binding
in virally-infected cells.
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BJAB vs. KSHV WT
7.00
6.00
p = 0.7295

Number of Tumors

5.00
4.00
3.00
2.00
1.00
0.00

BJAB

KSHV WT

Figure 10. KSHV does not affect the number of tumors derived from injected mice. Each tumor was carefully
excised from the mice and numbered at 5 weeks. The total number of tumors in each mouse from both groups was
then analyzed. (n=12, n=11)
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BJAB vs. KSHV WT
3.50
3.00
p = 0.0401*

Tumor Mass (g)

2.50
2.00
1.50
1.00
0.50
0.00

BJAB

KSHV WT

Figure 11. KSHV impacts mass of tumors in immortalized BJAB and KSHV WT-injected mice. Each tumor
was carefully excised from the mice and weighed at 5 weeks. The total weight of each group was then analyzed. (*
indicates a statistical significance less than p = 0.05 according to a pooled t-test analysis) (n=12, n=11)
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Figure 12. FACS analysis comparison of cultured immortalized BJAB and KSHV WT-injected BJAB cells.
A, Frequency of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30; B, Mean
fluorescence intensity of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30. (*
indicates a statistical significance less than p = 0.05 according to a pooled t-test analysis)
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Figure 13. FACS analysis comparison of cultured immortalized BJAB cells and those extracted from tumors.
A, Frequency of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30; B, Mean
fluorescence intensity of CD45+ cells, which display markers for GFP, CD19, CD20, CD22, CD138, and CD30. (*
indicates a statistical significance less than p = 0.05 according to a pooled t-test analysis)
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Figure 14. FACS analysis comparison of immortalized BJAB and KSHV WT-injected BJAB cells extracted
from tumors. A, Frequency of CD45+ and propidium iodine-negative populations, which display markers for GFP,
CD19, CD20, CD22, CD138, and CD30; B, Mean fluorescence intensity of CD45+ cells, which display markers
for GFP, CD19, CD20, CD22, CD138, and CD30. (* indicates a statistical significance less than p = 0.05 according
to a pooled t-test analysis)
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Discussion
The initial hypothesis did not anticipate tumors from the secondary negative control, i.e. uninfected
immortalized B cells (BJAB). It was expected that there would be a higher number of tumors and higher
tumor mass in the wild-type KSHV injected mice compared with uninfected BJAB cells, considering
KSHV is an oncogenic virus. This did not turn out to be the case.
Analysis of Tumors
There was no significant difference between the number of tumors in BJAB-injected mice and KSHV
WT-injected mice. Both types resulted in an average number of tumors between 3 and 4. However, the
size of the tumors was significantly different.
KSHV-infected cells produced smaller tumors than the oncogenic B cell line used in this experiment
(BJAB). Not only was the size of tumors present with the oncogenic virus expected to be larger than that
for the immortalized B cell line, but tumors themselves were not predicted for the immortalized cells.
It was hoped that the study of cell markers would shed more light on these results. The markers that were
quantified included: CD19+, a B cell marker; CD20+, a B cell marker that aids in differentiation into
plasma cells; CD22+, a regulatory molecule of B cell interactions; CD30+, a TNF receptor superfamily
can mediate signal transduction events that can Stimulate Proliferation or initiate apoptotic cell death
pathway; CD45+, a leukocyte marker that aids in regulating cell growth and differentiation;CD138+, a
plasma cell marker which aids in cell proliferation and migration87.
Impact of KSHV on human B cell markers in culture
A preliminary phenotypic analysis was performed for both KSHV WT-infected BJAB cells and uninfected
BJAB cells within culture before injection into the mice. This allowed us to see any patterns within these
cells before tumor-growth. WT-infected BJAB cells displayed a higher percentage of CD45+ and CD20+
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markers in culture compared to BJAB cells. WT-infected BJAB cells were also seen to have lower CD22+
markers compared to negatively-infected BJAB cells. We can assume that these differences are due to the
selection process made during the development of both of these virally-infected B cells.
Impact of KSHV on B cell makers in both infected and uninfected cells after tumor development
After excising the tumors we looked at the profiles of the two cell groups after tumor development. When
comparing each group of cells before and after infection we see that, generally, expression decreases in
vivo vs. in vitro - except in the case of CD30+ cells, which increase. This trend of decreasing markers can
be explained through the common phenomenon of cell de-differentiation throughout cancer development.
Cellular differentiation is the process whereby a cell changes from one cell type to another in order to
specialize in a specific function88. Dedifferentiation, on the other hand, is a phenomenon seen throughout
the conversion of a normal cell into an oncogenic one. These cells become less specialized as they revert
to an earlier developmental stage to survive. Two major nonexclusive hypotheses of the cellular origin of
cancer are that malignancy arises from either stem cells experiencing maturation arrest or dedifferentiation
of mature cells that retain the ability to proliferate89.
A common theme exhibited in both strains is the increase in CD30+ cells after tumorigenesis. A tumor
necrosis factor, CD30 (or TNFRSF8) is a cell membrane protein found on activated T and B cells90.
Stimulation of CD30 has been shown to lead to proliferation as well as apoptotic death91. The antiapoptotic effects of CD30 are mediated through the C D30-TRAF-NF-κB pathway92,93; the cytoplasmic
tail of CD30 associating with TNF receptor-associated factors (TRAF) and activating NF-κB transcription
factors94. Thus, we hypothesize that the increased CD30 levels in uninfected BJAB cells may cause an
increase in anti-apoptotic genes, resulting in larger tumors.
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Impact of KSHV on human B cell markers in cells extracted from tumors
When we compare the expression profiles of both BJAB cells and KSHV WT-infected BJAB cells, after
tumor growth, we see a few differences. This may be merely due to the selection process made during the
construction of the KSHV-infected BJAB cells and other lineage-selection processes, as they display the
same patterns both before and after infection. We do notice that CD30 remains an irregularity, of which
we see that those cells containing KSHV express much less CD30 compared with those cells without the
virus. This may indicate that KSHV has a method of controlling CD30 expression; this may allow virallyinfected cancerous cells to survive longer within the host undetected, it may be possible that smaller
tumors indicate increased viability of the virus within the tumor, or potentially, the virus is trying not to
kill the host as quickly as it might if it developed larger tumors.
Summary
The lack of significant change in overall tumor mass, and the marginally significant increase in tumor
numbers associated with vIL-6 described in the previous chapter led to the further studies to compare
uninfected cells with those containing KSHV. Smaller massed tumors were seen in those oncogenic cells
infected with wild-type KSHV compared to uninfected immortalized B cells, although no difference in
the number of tumors was observed. This indicates that the virus somehow slows tumor development.
Lower levels of CD30+ cells were also seen in cells infected with wild-type KSHV compared to uninfected
immortalized B cells. This may play a role in the differences in tumor development that we see between
the different cell groups, as CD30 could be aiding in a lack of apoptosis in immortalized B cells. More
studies must be done in order to evaluate how this could be advantage for the virus.
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Conclusion
Our initial hypothesis was that viral interleukin-6 is necessary for tumor development in larger tumors
such as those found in MCD; therefore, when present, it is expected to increase tumor mass and promote
angiogenesis as well as metastasis of the tumor. After preliminary data was acquired, we focused on two
different areas of KSHV oncogenesis: the role of vIL-6 in KSHV-associated cancers, and the implications
of a KSHV infection on the immortalized cell-line, BJAB. By obtaining a strain of KSHV with a vIL-6
knockout, we were able to investigate the role of the virally-produced cytokine. Based upon the subsequent
cancer growth in twelve mice, the results indicated no significant change in overall tumor mass, but an
appreciably higher number of tumors relating to the presence of vIL-6. While the statistical significance
of the higher number of tumors was below the 95th percentile t-test, it is likely that a higher subject number
would produce a clear statistical significance; this would indicate that vIL-6 increases the number of
tumors compared with the vIL-6 knockout strain. The various mechanisms associated with the presence
of the protein may allow the virus to increase the spread of cancer within an injected host, even though
the tumors do not increase in mass. Along with this preliminary tumor analysis, the cell-surface phenotype
was analyzed. Examination of these variables showed that CD30 markers increased in frequency within
in vivo cells compared to cultured cells; however, vIL-6 seemed to inhibit the increase of CD30 relative
to the mutant cells that did not contain vIL-6. In order to fully understand how this relationship affects
viral oncogenesis, further investigation into the role of CD30 in KSHV infections is needed. This would
also allow for the increased understanding necessary to make final conclusions as to whether the vIL6
protein could be used as a target for cancer treatment in the future.
A second course of study was then undertaken to further understand how a KSHV-infection could affect
immortalized cells transplanted into an immunocompromised murine host. Initial tumor analysis indicated
tumors with lower mass in KSHV-infected cells compared to uninfected immortalized B cells. This was
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interesting as it indicates that the viral-infection of a known oncogenic virus decreases tumor development.
Further investigation with expression profiles was performed for a more complete study. This showed
lower levels of CD30+ cells were present in KSHV-infected cells compared to the uninfected
immortalized B cells. If CD30 is considered to be playing a role in anti-apoptotic gene expression in this
type of oncogenesis, this could explain the differences in tumor mass that we see between the two cell
groups. The question then follows; why would an oncogenic virus be avoiding anti-apoptotic gene
expression? More studies must be done in order to evaluate how this could be advantage for the virus, and
what exact mechanisms of CD30 are being use in these types of cancers.
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Appendix
Table 1: Raw tumor data. Statistics were performed using a standard t-test on JMP statistical analysis program,
with error taken using the 95% confidence. The outlier from the KSHV WT-infected mice was removed from the
study.

Cell
Type
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB
BJAB

Number
of
Tumors
1
1
10
10
5
9
1
3
1
1
1
4

Total
Mass (g)
5.66
3.51
1.5021
1.6376
0.418
1.0661
0.9125
1.32206
4.415
2.7748
4.11124
1.8542

Cell
Type
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT

Number
of
Tumors
2
7
5
8
4
1
2
2
4
2
1
0
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Total
Mass (g)
1.704
0.5512
1.3784
4.4703
0.435
0.0952
0.5767
1.4436
0.5186
0.1893
0.6772
0

Cell
Type
vIL6vIL6vIL6vIL6vIL6vIL6vIL6vIL6vIL6vIL6vIL6vIL6-

Number
of
Tumors
4
2
1
3
4
2
1
2
1
1
1
1

Total
Mass (g)
1.2713
1.3787
0.9561
1.1491
0.6498
0.8614
1.4577
1.4213
1.6854
1.1095
1.8646
0.9918

